Drug Profile
Research programme: ketamine deuterated - Teva Pharmaceutical Industries
Alternative Names: Deuterium-containing ketamine - Teva Pharmaceutical IndustriesLatest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Auspex Pharmaceuticals
- Developer Teva Pharmaceutical Industries
- Class Analgesics; Inorganic deuterium compounds; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Pain in USA (unspecified route) (Teva Pharmaceutical website, September 2023)
- 28 Apr 2018 No recent reports of development identified for preclinical development in Pain in USA
- 05 May 2015 Auspex Pharmaceuticals has been acquired by Teva Pharmaceutical Industries